Cargando…

49. Clinical Utility of Oseltamivir Restriction Policy

BACKGROUND: Inappropriate use of oseltamivir and antibiotics for upper respiratory tract infections may increase risk of microbial resistance. Restriction policies have been used to curtail inappropriate use of oseltamivir and antimicrobials in suspected or confirmed influenza patients. We assessed...

Descripción completa

Detalles Bibliográficos
Autores principales: Kale-Pradhan, Pramodini, Manuel, Martin, Johnson, Leonard B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776335/
http://dx.doi.org/10.1093/ofid/ofaa439.094
_version_ 1783630658485092352
author Kale-Pradhan, Pramodini
Manuel, Martin
Johnson, Leonard B
author_facet Kale-Pradhan, Pramodini
Manuel, Martin
Johnson, Leonard B
author_sort Kale-Pradhan, Pramodini
collection PubMed
description BACKGROUND: Inappropriate use of oseltamivir and antibiotics for upper respiratory tract infections may increase risk of microbial resistance. Restriction policies have been used to curtail inappropriate use of oseltamivir and antimicrobials in suspected or confirmed influenza patients. We assessed the impact of Infectious Diseases (ID) consult on the management of oseltamivir and concomitant antibiotics. METHODS: A single‐center, retrospective study of patients ≥ 17 years, admitted for greater than 24 hours who received oseltamivir from October 1, 2018 to May 1, 2019 were evaluated. Demographics, Charlson Weighted Index of Comorbidity (CWIC), length of hospital stay (LOS), discharge disposition, rapid flu test, respiratory viral panel, sputum and blood cultures, antibiotic regimen and duration were collected. Continuous variables were analyzed using Students t‐test and categorical variables with Chi square test. RESULTS: 298 patients were screened and 182 patients met the inclusion criteria. Please see table below for results. Oseltamivir was appropriately continued in 92.9% in the ID consult group compared to 89.3% in the non-ID consult group (p = 0.51). Antibiotic interventions were appropriate in 63.2% of the ID consult group compared to 40% in non-ID group (p = 0.36). Results Summary [Image: see text] CONCLUSION: Oseltamivir interventions were appropriate and similar in between groups. Further, there was higher percentage of appropriate antibiotic interventions in the ID physician group. Duration of antibiotics was longer in the ID physicians consulted group which may be due to higher severity of illness in the group. DISCLOSURES: All Authors: No reported disclosures
format Online
Article
Text
id pubmed-7776335
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-77763352021-01-07 49. Clinical Utility of Oseltamivir Restriction Policy Kale-Pradhan, Pramodini Manuel, Martin Johnson, Leonard B Open Forum Infect Dis Poster Abstracts BACKGROUND: Inappropriate use of oseltamivir and antibiotics for upper respiratory tract infections may increase risk of microbial resistance. Restriction policies have been used to curtail inappropriate use of oseltamivir and antimicrobials in suspected or confirmed influenza patients. We assessed the impact of Infectious Diseases (ID) consult on the management of oseltamivir and concomitant antibiotics. METHODS: A single‐center, retrospective study of patients ≥ 17 years, admitted for greater than 24 hours who received oseltamivir from October 1, 2018 to May 1, 2019 were evaluated. Demographics, Charlson Weighted Index of Comorbidity (CWIC), length of hospital stay (LOS), discharge disposition, rapid flu test, respiratory viral panel, sputum and blood cultures, antibiotic regimen and duration were collected. Continuous variables were analyzed using Students t‐test and categorical variables with Chi square test. RESULTS: 298 patients were screened and 182 patients met the inclusion criteria. Please see table below for results. Oseltamivir was appropriately continued in 92.9% in the ID consult group compared to 89.3% in the non-ID consult group (p = 0.51). Antibiotic interventions were appropriate in 63.2% of the ID consult group compared to 40% in non-ID group (p = 0.36). Results Summary [Image: see text] CONCLUSION: Oseltamivir interventions were appropriate and similar in between groups. Further, there was higher percentage of appropriate antibiotic interventions in the ID physician group. Duration of antibiotics was longer in the ID physicians consulted group which may be due to higher severity of illness in the group. DISCLOSURES: All Authors: No reported disclosures Oxford University Press 2020-12-31 /pmc/articles/PMC7776335/ http://dx.doi.org/10.1093/ofid/ofaa439.094 Text en © The Author 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Poster Abstracts
Kale-Pradhan, Pramodini
Manuel, Martin
Johnson, Leonard B
49. Clinical Utility of Oseltamivir Restriction Policy
title 49. Clinical Utility of Oseltamivir Restriction Policy
title_full 49. Clinical Utility of Oseltamivir Restriction Policy
title_fullStr 49. Clinical Utility of Oseltamivir Restriction Policy
title_full_unstemmed 49. Clinical Utility of Oseltamivir Restriction Policy
title_short 49. Clinical Utility of Oseltamivir Restriction Policy
title_sort 49. clinical utility of oseltamivir restriction policy
topic Poster Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776335/
http://dx.doi.org/10.1093/ofid/ofaa439.094
work_keys_str_mv AT kalepradhanpramodini 49clinicalutilityofoseltamivirrestrictionpolicy
AT manuelmartin 49clinicalutilityofoseltamivirrestrictionpolicy
AT johnsonleonardb 49clinicalutilityofoseltamivirrestrictionpolicy